Rigel

Rigel's mission is to become a source of novel, small-molecule drugs to address large, unmet medical needs. We have initiated four development programs: asthma/allergy, hepatitis C, rheumatoid arthritis and oncology. Our strategy is to initiate clinical trials with at least one new product candidate annually and to pursue partnerships with pharmaceutical and biotechnology companies for late-stage clinical development and commercialization of those product candidates. R112 for allergic rhinitis has completed a Phase II clinical trial. We are in the process of selecting a lead product candidate for the treatment of hepatitis C, to move into the clinic. We initiated safety trials of R406 for the treatment of rheumatoid arthritis at the end of 2004. We plan to pursue clinical development with additional product candidates for indications in oncology and asthma. Our research efforts are focused in the areas of immunology/ inflammation, virology and oncology.

For information on how to contact Rigel Pharmaceuticals, please visit the contact us page.

For current job opportunities at Rigel Click here

Contact address:

Rigel Pharmaceuticals, Inc.
1180 Veterans Boulevard
South San Francisco, CA 94080
phone: 650.624.1100
fax: 650.624.1101
email: communications@rigel.com